Ofost (Oxytocin)

Oxytocin binds to oxytocin receptors on the uterine myometrium, activating a signaling cascade that raises intracellular calcium. The calcium increase drives actin‑myosin interaction, producing coordinated uterine contractions that help initiate or strengthen labor and reduce bleeding after delivery.

The dose of Ofost is determined by the prescribing clinician based on the specific clinical situation, patient characteristics, and response. Standard regimens vary, and the prescriber will adjust the amount and rate of administration to achieve the desired uterine activity.

Ofost is classified as Pregnancy Category B, indicating that it is generally considered safe for use during labor under medical supervision. It is not intended for use during pregnancy for other indications, and limited data exist on excretion in breast milk; clinicians weigh benefits against potential risks.

To order Ofost, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative to oxytocin for uterine stimulation is prostaglandin E2 (misoprostol). Oxytocin has a rapid onset, is easily titratable, and is preferred for controlled induction or augmentation, whereas misoprostol offers oral or vaginal routes but may have a less predictable effect and a higher risk of fever.

Ofost should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Keep it in the original packaging until use to maintain sterility and potency.

Ofost is supplied as a sterile injectable solution and may be given intramuscularly or intravenously. Administration is performed by qualified healthcare professionals, typically using a slow IV infusion or a controlled IM injection, with dosage adjusted according to uterine response and clinical monitoring.

Serious risks include uterine hyperstimulation leading to fetal distress, water intoxication causing hyponatremia, myocardial ischemia or infarction, severe hypertension, and anaphylactic reactions. Continuous fetal and maternal monitoring is essential to detect and manage these complications promptly.

Ofost is contraindicated in patients with known hypersensitivity to oxytocin, severe cardiovascular disease, uncontrolled hypertension, fetal distress, or when the uterus is already hyperstimulated. It should also be avoided in cases where labor is not indicated, such as certain obstetric complications.